| 8:30 AM-9:30 AM | Neurobiology and Genetic Factors of Schizophrenia Description:1. Examine the state of the science in understanding the neurobiology of schizophrenia in order to improve understanding of new developments in these conditions.
2. Outline the latest research into the genetic factors and neuroplasticity that may contribute to the etiology of schizophrenia.
3. Compare and contrast available treatments for schizophrenia, with a focus on management of treatment-resistant patients.
4. Outline emerging strategies for treating schizophrenia, and compare their method of action, safety, and efficacy to those of established therapies. Include possible treatments for prodromes of schizophrenia.
Daniel Weinberger, MD ,
National Institute of Mental Health,
Olney, MD, National Institutes Of Health ,
Bethesda, MD |
| 9:45 AM-10:45 AM | Modern Psychotropic Drug Treatment of Schizophrenia Description:1. Examine the state of the science in understanding the neurobiology of schizophrenia in order to improve understanding of new developments in these conditions.
2. Outline the latest research into the genetic factors and neuroplasticity that may contribute to the etiology of schizophrenia.
3. Compare and contrast available treatments for schizophrenia, with a focus on the management of treatment-resistant patients.
4. Outline emerging strategies for treating schizophrenia, and compare their method of action, safety, and efficacy to those of established therapies. Include possible treatments for prodromes of schizophrenia.
Carl Salzman, MD,
Professor of Psychiatry,
Harvard Medical School,
Boston, MA, Director of Psychopharmacology,
Massachusetts Mental Health Center,
|
| 11:00 AM-12:00 PM | Panel Q&A on Schizophrenia Carl Salzman, MD,
Professor of Psychiatry,
Harvard Medical School,
Boston, MA, Director of Psychopharmacology,
Massachusetts Mental Health Center,
Daniel Weinberger, MD ,
National Institute of Mental Health,
Olney, MD, National Institutes Of Health ,
Bethesda, MD |
| 12:15 PM-1:15 PM | Lunch Session with Schizophrenia Case Study Workshop Carl Salzman, MD,
Professor of Psychiatry,
Harvard Medical School,
Boston, MA, Director of Psychopharmacology,
Massachusetts Mental Health Center,
Daniel Weinberger, MD ,
National Institute of Mental Health,
Olney, MD, National Institutes Of Health ,
Bethesda, MD |
| 1:30 PM-2:30 PM | Bipolar Disorder: Epidemiology and Morbidity; Introduction to Acute Phase and Long-Term Treatment: Emphasis on Lithium as a Model Description:1. Examine the epidemiology, diagnosis, course of illness, and morbidity of type I and II bipolar disorders, with emphasis on bipolar depression as a major diagnostic and therapeutic challenge.
2. Review treatments for acute mania and introduce the concept of long-term prophylaxis, using data on current long-term and extensively studied options.
3. Review available treatments for bipolar depression, and consider pros and cons of including antidepressants with mood stabilizers.
4. Compare long-term options for the treatment of bipolar I and II disorders, including anticonvulsants and current and emerging antipsychotic agents.
5. Discuss management of complex bipolar disorder patients, including patients with mixed states, psychotic features, rapid cycling, comorbid anxiety or substance-use disorders, cognitive impairment, disability, high suicide risks, as well as juvenile and geriatric cases.Ross Baldessarini, MD ,
McLean Hospital,
Belmont, MA, Harvard Medical School,
Boston, MA |
| 2:45 PM-3:45 PM | Newer and Emerging Treatments for Bipolar Disorder: Acute and Maintenance Management Description:1. Examine the epidemiology, diagnosis, course of illness, and morbidity of type I and II bipolar disorders, with emphasis on bipolar depression as a major diagnostic and therapeutic challenge.
2. Review treatments for acute mania and introduce the concept of long-term prophylaxis, using data on current long-term and extensively studied options.
3. Review available treatments for bipolar depression, and consider pros and cons of including antidepressants with mood stabilizers.
4. Compare long-term options for the treatment of bipolar I and II disorders, including anticonvulsants and current and emerging antipsychotic agents.
5. Discuss management of complex bipolar disorder patients, including patients with mixed states, psychotic features, rapid cycling, comorbid anxiety or substance-use disorders, cognitive impairment, disability, high suicide risks, as well as juvenile and geriatric cases.Nassir S. Ghaemi, MD,
Emory University School of Medicine,
Atlanta, GA |
| 4:00 PM-5:30 PM | Panel Q&A and Case Study on Bipolar Ross Baldessarini, MD ,
Harvard Medical School,
Boston, MA, McLean Hospital,
Belmont, MA Nassir S. Ghaemi, MD,
Emory University School of Medicine,
Atlanta, GA |
